Certara (NASDAQ:CERT) Sets New 1-Year Low – Here’s Why

Shares of Certara, Inc. (NASDAQ:CERT) reached a new 52-week low during trading on Friday . The company traded as low as $9.25 and last traded at $9.44, with a volume of 105418 shares traded. The stock had previously closed at $9.78.

Analyst Ratings Changes

CERT has been the subject of a number of research analyst reports. Barclays increased their target price on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on shares of Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Stephens reiterated an “overweight” rating and issued a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.83.

Certara Trading Down 2.4 %

The company has a market capitalization of $1.54 billion, a PE ratio of -47.75, a PEG ratio of 9.29 and a beta of 1.64. The company has a fifty day simple moving average of $12.14 and a 200-day simple moving average of $11.41. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in shares of Certara by 1.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 699,575 shares of the company’s stock valued at $8,192,000 after buying an additional 12,720 shares during the period. State Street Corp grew its position in Certara by 3.4% in the third quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after acquiring an additional 122,411 shares during the period. Jane Street Group LLC increased its stake in Certara by 2.6% during the third quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock worth $1,726,000 after acquiring an additional 3,732 shares during the last quarter. Barclays PLC raised its position in Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after purchasing an additional 46,880 shares during the period. Finally, 272 Capital LP acquired a new stake in shares of Certara during the 3rd quarter worth about $586,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.